Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus etoposide and platinum as first-line treatment for extensive-stage small-cell lung cancer with liver metastases
ChiCTR2400092388Phase 2Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab, etoposide, carboplatin and cisplatin in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival. Started Nov 2024; status: completed.
02
Drugs
envafolimabetoposidecarboplatincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400092388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092388.